Targeting WEE1 Kinase in Gynecological Malignancies

References

• Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432(7015):316–323. doi:10.1038/nature03097
   PubMed Web of Science ®Google Scholar
• Beck H, Nähse-Kumpf V, Larsen MS, et al. Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption. Mol Cell Biol. 2012;32(20):4226–4236. doi:10.1128/mcb.00412-12
   PubMed Web of Science ®Google Scholar
• Moiseeva TN, Qian C, Sugitani N, Osmanbeyoglu HU, Bakkenist CJ. WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells. Proc Natl Acad Sci USA. 2019;116(48):23891–23893. doi:10.1073/pnas.1915108116
   PubMed Web of Science ®Google Scholar
• Kellogg DR. Wee1-dependent mechanisms required for coordination of cell growth and cell division. J Cell Sci. 2003;116(Pt 24):4883–4890. doi:10.1242/jcs.00908
   PubMed Web of Science ®Google Scholar
• Domínguez-Kelly R, Martín Y, Koundrioukoff S, et al. Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease. J Cell Biol. 2011;194(4):567–579. doi:10.1083/jcb.201101047
   PubMed Web of Science ®Google Scholar
• Krajewska M, Heijink AM, Bisselink YJ, et al. Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. Oncogene. 2013;32(24):3001–3008. doi:10.1038/onc.2012.296
   PubMed Web of Science ®Google Scholar
• Cole AJ, Dwight T, Gill AJ, et al. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing. Sci Rep. 2016;6:26191. doi:10.1038/srep26191
   PubMed Web of Science ®Google Scholar
• Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73. doi:10.1038/nature12113
   PubMed Web of Science ®Google Scholar
• Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990;248(4951):76–79. doi:10.1126/science.2157286
   PubMed Web of Science ®Google Scholar
• Jazayeri A, Falck J, Lukas C, et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol. 2006;8(1):37–45. doi:10.1038/ncb1337
   PubMed Web of Science ®Google Scholar
• Elbæk CR, Petrosius V, Sørensen CS. WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry. Mutat Res. 2020;819-820:111694. doi:10.1016/j.mrfmmm.2020.111694
   PubMed Web of Science ®Google Scholar
• Guimaraes DP, Hainaut P. TP53: a key gene in human cancer. Biochimie. 2002;84(1):83–93. doi:10.1016/s0300-9084(01)01356-6
   PubMed Web of Science ®Google Scholar
• Matheson CJ, Backos DS, Reigan P. Targeting WEE1 Kinase in Cancer. Trends Pharmacol Sci. 2016;37(10):872–881. doi:10.1016/j.tips.2016.06.006
   PubMed Web of Science ®Google Scholar
• Hirai H, Iwasawa Y, Okada M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 2009;8(11):2992–3000. doi:10.1158/1535-7163.mct-09-0463
   PubMed Web of Science ®Google Scholar
• Wang Y, Li J, Booher RN, et al. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res. 2001;61(22):8211–8217.
   PubMed Web of Science ®Google Scholar
• Palmer BD, Thompson AM, Booth RJ, et al. 4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution. J Med Chem. 2006;49(16):4896–4911. doi:10.1021/jm0512591
   PubMed Web of Science ®Google Scholar
• Huang PQ, Boren BC, Hegde SG, et al. Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer. J Med Chem. 2021;64(17):13004–13024. doi:10.1021/acs.jmedchem.1c01121
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Gietema JA, Desar IME, et al. 601TiP First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours. Ann Oncol. 2020;31:S501–2. doi:10.1016/j.annonc.2020.08.715
   PubMedGoogle Scholar
• Lin -C-C, Grewal JS, Sommerhalder D, et al. A Phase 1 dose-escalation and -expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors. J clin oncol. 2022;40(16_suppl):e15052. doi:10.1200/JCO.2022.40.16_suppl.e15052
   Google Scholar
• Leijen S, van Geel RM, Sonke GS, et al. Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months. J Clin Oncol. 2016;34(36):4354–4361. doi:10.1200/jco.2016.67.5942
   PubMed Web of Science ®Google Scholar
• Oza AM, Estevez-Diz M, Grischke EM, et al. A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer. Clin Cancer Res. 2020;26(18):4767–4776. doi:10.1158/1078-0432.ccr-20-0219
   PubMed Web of Science ®Google Scholar
• Lheureux S, Cristea MC, Bruce JP, et al. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, Phase 2 trial. Lancet. 2021;397(10271):281–292. doi:10.1016/s0140-6736(20)32554-x
   PubMed Web of Science ®Google Scholar
• Moore KN, Chambers SK, Hamilton EP, et al. Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: an Open-Label, Four-Arm, Phase II Study. Clin Cancer Res. 2022;28(1):36–44. doi:10.1158/1078-0432.Ccr-21-0158
   PubMed Web of Science ®Google Scholar
• Liu J, Oza AM, Colombo N, Oaknin A. ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma. Int J Gynecol Cancer. 2022;32(1):89–92. doi:10.1136/ijgc-2021-003144
   PubMed Web of Science ®Google Scholar
• Meng X, Bi J, Li Y, et al. AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations. Cancers. 2018;10(5):149.
   PubMed Web of Science ®Google Scholar
• Zhang M, Dominguez D, Chen S, et al. WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability. Oncol Lett. 2017;14(3):3580–3586. doi:10.3892/ol.2017.6584
   PubMed Web of Science ®Google Scholar
• Li J, Wang Y, Sun Y, Lawrence TS. Wild-type TP53 inhibits G(2)-phase checkpoint abrogation and radiosensitization induced by PD0166285, a WEE1 kinase inhibitor. Radiation Res. 2002;157(3):322–330. doi:10.1667/0033-7587(2002)157
   PubMed Web of Science ®Google Scholar
• Lee YY, Cho YJ, Shin SW, et al. Anti-Tumor Effects of Wee1 Kinase Inhibitor with Radiotherapy in Human Cervical Cancer. Sci Rep. 2019;9(1):15394. doi:10.1038/s41598-019-51959-3
   PubMedGoogle Scholar
• Cuneo KC, Morgan MA, Davis MA, et al. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress. Int J Radiat Oncol Biol Phys. 2016;95(2):782–790. doi:10.1016/j.ijrobp.2016.01.028
   PubMed Web of Science ®Google Scholar
• Chiappa M, Guffanti F, Anselmi M, et al. Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells. Cancers. 2022;14(7):1807.
   PubMed Web of Science ®Google Scholar
• Fang Y, McGrail DJ, Sun C, et al. Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. Cancer Cell. 2019;35(6):851–867.e7. doi:10.1016/j.ccell.2019.05.001
   PubMed Web of Science ®Google Scholar
• Xu H, George E, Kinose Y, et al. CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. Cell Rep Med. 2021;2(9):100394. doi:10.1016/j.xcrm.2021.100394
   PubMedGoogle Scholar
• Wu X, Kang X, Zhang X, et al. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade. Cancer Sci. 2021;112(11):4444–4456. doi:10.1111/cas.15108
   PubMed Web of Science ®Google Scholar
• Gonzalez-Ochoa E, Milosevic M, Corr B, et al. A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers. Int J Gynecol Cancer. 2023;33(8):1208–1214. doi:10.1136/ijgc-2023-004491
   PubMed Web of Science ®Google Scholar
• Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B, Flørenes VA. Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions. Gynecol Oncol. 2014;135(1):118–124. doi:10.1016/j.ygyno.2014.07.102
   PubMed Web of Science ®Google Scholar
• Iorns E, Lord CJ, Grigoriadis A, et al. Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One. 2009;4(4):e5120. doi:10.1371/journal.pone.0005120
   PubMed Web of Science ®Google Scholar
• Magnussen GI, Hellesylt E, Nesland JM, Trope CG, Flørenes VA, Holm R. High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients. BMC Cancer. 2013;13:288. doi:10.1186/1471-2407-13-288
   PubMed Web of Science ®Google Scholar
• Li J, Lu J, Xu M, et al. ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models. J Clin Invest. 2023;133(2).
   Web of Science ®Google Scholar
• PosthumaDeBoer J, Würdinger T, Graat HC, et al. WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer. 2011;29(11):156. doi:10.1186/1471-2407-11-156
   Google Scholar
• Esposito F, Giuffrida R, Raciti G, Puglisi C, Forte S. Wee1 Kinase: a Potential Target to Overcome Tumor Resistance to Therapy. Int J Mol Sci. 2021;22(19).
   Web of Science ®Google Scholar
• Mir SE, De Witt Hamer PC, Krawczyk PM, et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell. 2010;18(3):244–257. doi:10.1016/j.ccr.2010.08.011
   PubMed Web of Science ®Google Scholar
• Buisson R, Niraj J, Rodrigue A, et al. Coupling of Homologous Recombination and the Checkpoint by ATR. Mol Cell. 2017;65(2):336–346. doi:10.1016/j.molcel.2016.12.007
   PubMed Web of Science ®Google Scholar
• Li F, Guo E, Huang J, et al. mTOR inhibition overcomes primary and acquired resistance to Wee1 inhibition by augmenting replication stress in epithelial ovarian cancers. Am J Cancer Res. 2020;10(3):908–924.
   PubMed Web of Science ®Google Scholar
• Xiao R, You L, Zhang L, et al. Inhibiting the IRE1α Axis of the Unfolded Protein Response Enhances the Antitumor Effect of AZD1775 in TP53 Mutant Ovarian Cancer. Adv. Sci. 2021:2105469. doi:10.1002/advs.202105469
   Web of Science ®Google Scholar
• Rosen DG, Yang G, Deavers MT, et al. Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer. 2006;106(9):1925–1932. doi:10.1002/cncr.21767
   PubMed Web of Science ®Google Scholar
• Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489–494. doi:10.1038/nature14410
   PubMed Web of Science ®Google Scholar
• Guo E, Xiao R, Wu Y, et al. WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway. J Exp Med. 2022;219(1).
   Web of Science ®Google Scholar
• Takebe N, Naqash AR, O’Sullivan Coyne G, et al. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2021;27(14):3834–3844. doi:10.1158/1078-0432.ccr-21-0329
   PubMed Web of Science ®Google Scholar
• Tolcher A, Mamdani H, Chalasani P, et al. Clinical Activity of Single-Agent ZN-c3, an Oral WEE1 Inhibitor, in a Phase 1 Dose-Escalation Trial in Patients with Advanced Solid Tumors. Philadelphia, Pa: AMER ASSOC CANCER RESEARCH 615 CHESTNUT ST, 17TH FLOOR; 2021.
   Google Scholar
• Dellino M, Cerbone M, Laganà AS, et al. Upgrading Treatment and Molecular Diagnosis in Endometrial Cancer-Driving New Tools for Endometrial Preservation? Int J Mol Sci. 2023;24(11).
   Web of Science ®Google Scholar
• McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol. 2018;244(5):538–549. doi:10.1002/path.5034
   PubMed Web of Science ®Google Scholar
• Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333–339. doi:10.1038/nature12634
   PubMed Web of Science ®Google Scholar
• McGunigal M, Liu J, Kalir T, Chadha M, Gupta V. Survival Differences Among Uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial Cancers: a National Cancer Database Analysis. Int J Gynecol Cancer. 2017;27(1):85–92. doi:10.1097/igc.0000000000000844
   PubMed Web of Science ®Google Scholar
• Zhao S, Choi M, Overton JD, et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci USA. 2013;110(8):2916–2921. doi:10.1073/pnas.1222577110
   PubMed Web of Science ®Google Scholar
• Liu JF, Xiong N, Campos SM, et al. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol. 2021;39(14):1531–1539. doi:10.1200/jco.20.03167
   PubMed Web of Science ®Google Scholar
• Miwa K, Miyamoto S, Kato H, et al. The role of p53 inactivation in human cervical cell carcinoma development. Br J Cancer. 1995;71(2):219–226. doi:10.1038/bjc.1995.47
   PubMed Web of Science ®Google Scholar
• Benard VB, Thomas CC, King J, Massetti GM, Doria-Rose VP, Saraiya M. Vital signs: cervical cancer incidence, mortality, and screening - United States, 2007-2012. MMWR Morb Mortal Wkly Rep. 2014;63(44):1004–1009.
   PubMed Web of Science ®Google Scholar
• Valenti G, Vitale SG, Tropea A, Biondi A, Laganà AS. Tumor markers of uterine cervical cancer: a new scenario to guide surgical practice? Updates Surg. 2017;69(4):441–449. doi:10.1007/s13304-017-0491-3
   PubMed Web of Science ®Google Scholar
• Schutte T, Embaby A, Steeghs N, et al. Clinical development of WEE1 inhibitors in gynecological cancers: a systematic review. Cancer Treat Rev. 2023;115:102531. doi:10.1016/j.ctrv.2023.102531
   PubMed Web of Science ®Google Scholar